Èñòîðèÿ èíñòèòóòà
Íàöèîíàëüíûé èíñòèòóò ôòèçèàòðèè è
ïóëüìîíîëîãèè èì Ô.Ã. ßíîâñêîãî

Ïîñåòèòå íàøó ñòðàíèöóâ Facebook

 

Êëèíèêà
Êîíòàêòû

Ïåðåõîä íà òèòóëüíóþ ñòðàíèöóÏîèñê ïî ñàéòó

Óêðàèíñêèé ïóëüìîíîëîãè÷åñêèé æóðíàë

Îá èíñòèòóòå:

èñòîðèÿ,

îáùèå ïîëîæåíèÿ,

ñòðóêòóðà,

íàó÷íàÿ äåÿòåëüíîñòü,

ïëàíû ÍÈÐ,

ëå÷åáíî-äèàãíîñòè÷åñêàÿ ðàáîòà,

âåäóùèå ó÷åíûå

Íîâîñòè:

íîâèíêè íà ñàéòå

Íàøè èçäàíèÿ:

"Óêðàèíñêèé ïóëüìîíîëîãè÷åñêèé æóðíàë" (ÓÏÆ),
"Óêðàèíñêèé õèìèîòåðàïåâòè÷åñêèé æóðíàë" (ÓÕÆ),
"Àñòìà è àëëåðãèÿ"

Îðèãèíàëüíûå ñòàòüè:

îðèãèíàëüíûå íàó÷íûå ñòàòüè, ðàíåå íèãäå íå ïóáëèêîâàâøèåñÿ

Íîâîââåäåíèÿ:

ìåòîäè÷åñêèå ðåêîìåíäàöèè, èíôîðìàöèîííûå ïèñüìà,
âåäîìñòâåííûå èíñòðóêöèè,
íîâîââåäåíèÿ, ìîíîãðàôèè

Ïàòåíòû:

ïàòåíòû è àâòîðñêèå ñâèäåòåëüñòâà èíñòèòóòà

Îò÷åòû î ÍÈÐ:

ðåôåðàòû çàêîí÷åííûõ íàó÷íî-èññëåäîâàòåëüñêèõ ðàáîò

Ïîäãîòîâêà êàäðîâ:

àñïèðàíòóðà,

êëèíè÷åñêàÿ îðäèíàòóðà,
êóðñû èíôîðìàöèè è ñòàæèðîâêè,

â ïîìîùü àñïèðàíòó è ñîèñêàòåëþ

Íàó÷íûå ôîðóìû:

ðåçîëþöèè è îáðàùåíèÿ ñúåçäîâ, êîíôåðåíöèé, ñîâåùàíèé...

Âèðòóàëüíûå êîíôåðåíöèè:

âîïðîñû è îòâåòû ïî ïðîáëåìàì çàáîëåâàíèé îðãàíîâ äûõàíèÿ

Èíôîðìàöèÿ äëÿ ñïåöèàëèñòîâ:

îáçîðû ëèòåðàòóðû, ñòàòèñòè÷åñêàÿ èíôîðìàöèÿ, íîâîå â ëå÷åíèè òóáåðêóëåçà è íåñïåöèôè÷åñêèõ çàáîëåâàíèé ëåãêèõ...

Èíôîðìàöèÿ äëÿ íàñåëåíèÿ:

ïîëåçíàÿ èíôîðìàöèÿ î çàáîëåâàíèÿõ ëåãêèõ, èõ ïðîôèëàêòèêå è ëå÷åíèè

2014. - ¹ 2.
Ç̲ÑÒ / ÑÎÄÅÐÆÀÍÈÅ / CONTENTS

ÌÀÒÅвÀËÈ ÍÀÓÊÎÂÎ-ÏÐÀÊÒÈ×Íί ÊÎÍÔÅÐÅÍÖ²¯ / PROCEEDINGS OF THE CONFERENCE

 

ÂÑÒÓÏÍÅ ÑËÎÂÎ ÀÊÀÄÅ̲ÊÀ ÍÀÌÍ ÓÊÐÀ¯ÍÈ, ÏÐÎÔÅÑÎÐÀ Þ. ². ÔÅÙÅÍÊÀ
®

INTRODUCTORY WORD BY ACADEMICIAN OF NAMS OF UKRAINE, PROFESSOR YURIY FESHCHENKO
 

 

Þ. Ì. Ìîñòîâîé
ÖÈÔÐÈ, ÙÎ ÃÎÂÎÐßÒÜ ² ÌÎÂ×ÀÒÜ: ÐÎÇÄÓÌÈ ÏÐÎ ÕÎÇË, ÙÎ ÁÀÇÓÞÒÜÑß ÍÀ ÑÒÀÒÈÑÒÈ×ÍÎÌÓ ÀÍÀ˲Ç

®

Yu. M. Mostovoy
FIGURES WHICH SPEAKS AND KEEP SILENCE: REFLECTIONS ON COPD BASED ON STATISTICAL ANALYSIS
 

È. È. Âèøíèâåöêèé
ÕÎÇË Â ÓÊÐÀÈÍÅ: ×ÅÃÎ ÌÛ ÎÏÀÑÀÅÌÑß? ÂÎÏÐÎÑÛ ÁÅÇÎÏÀÑÍÎÑÒÈ ÈÍÃÀËßÖÈÎÍÍÛÕ ÑÐÅÄÑÒÂ

®

I. I. Vishnivetskiy
COPD IN UKRAINE: WHAT ARE WE REALLY AFRAID OF? SAFETY OF INHALED MEDICINES
 

Ò. À. Ïåðöåâà
ÒÅÐÀÏÈß ÕÎÇË: Ê ×ÅÌÓ ÍÀÄÎ ÑÒÐÅÌÈÒÜÑß?

®

T. A. Pertseva
COPD THERAPY: WHAT SHOULD WE STRIVE FOR?
 

ÑÎÂÐÅÌÅÍÍÛÅ ÏÎÄÕÎÄÛ Ê ÏÐÎÔÈËÀÊÒÈÊÅ È ËÅ×ÅÍÈÞ ÎÁÑÒÐÓÊÒÈÂÍÛÕ ÇÀÁÎËÅÂÀÍÈÉ ËÅÃÊÈÕ (ïî ìàòåðèàëàì ñèìïîçèóìà ïðè ïîääåðæêå êîìïàíèè Áåðèíãåð Èíãåëüõàéì)
®

MODERN APPROACHES TO PREVENTION AND TREATMENT OF OBSTRUCTIVE LUNG DISEASES (a symposium, supported by Boehringer Ingelheim)
 

Â. Ê. Ãàâðèñþê, À. È. ß÷íèê, Å. À. Ìåðåíêîâà
ÕÐÎÍÈ×ÅÑÊÎÅ ËÅÃÎ×ÍÎÅ ÑÅÐÄÖÅ Â ÑÂÅÒÅ ÏÎËÎÆÅÍÈÉ ÌÅÆÄÓÍÀÐÎÄÍÛÕ ÐÓÊÎÂÎÄÑÒ NICE-COPD È GOLD

®

V. K. Gavrisiuk, A. I. Yachnik, E. A. Merenkova
COR PULMONLE IN LIGHT OF INTERNATIONAL NICE-COPD AND GOLD GUIDELINES
 

Í. Å. Ìîíîãàðîâà
ÂÛÁÎÐ ÒÅÐÀÏÈÈ Ó ÏÀÖÈÅÍÒÎÂ Ñ ÂÛÑÎÊÈÌ ÐÈÑÊÎÌ ÎÁÎÑÒÐÅÍÈß ÕÎÇË

®

N. E. Monogarova
CHOICE OF THERAPY IN PATIENTS WITH HIGH RISK OF COPD EXACERBATION
 

Ë. È. Êîíîïêèíà
ÂËÈßÍÈÅ ÊÎÌÏËÀÅÍÑÀ ÍÀ ÐÅÇÓËÜÒÀÒÛ ËÅ×ÅÍÈß ÁÎËÜÍÛÕ ÕÐÎÍÈ×ÅÑÊÈÌ ÎÁÑÒÐÓÊÒÈÂÍÛÌ ÇÀÁÎËÅÂÀÍÈÅÌ ËÅÃÊÈÕ

®

L.I. Konopkina
EFFECT OF COMPLIANCE ON RESULTS OF TREATMENT OF COPD PATIENTS
 

 

À. Ï. Ãðèøèëî
ÈÑÏÎËÜÇÎÂÀÍÈÅ ÈÍÍÎÂÀÖÈÎÍÍÎÉ ÑÒÐÓÊÒÓÐÛ ÔËÓÒÈÊÀÇÎÍÀ ÏÐÎÏÈÎÍÀÒÀ  ËÅ×ÅÍÈÈ ÁÎËÜÍÛÕ ÕÐÎÍÈ×ÅÑÊÈÌ ÎÁÑÒÐÓÊÒÈÂÍÛÌ ÇÀÁÎËÅÂÀÍÈÅÌ ËÅÃÊÈÕ

®

A.P. Grishilo
USE OF INNOVATIVE STRUCTURE OF FLUTICASONE PROPIONATE IN TREATMENTS OF COPD PATIENTS
 

Ë. À. ßøèíà
ÄÎÊÀÇÀÒÅËÜÍÀß ÁÀÇÀ ÝÔÔÅÊÒÈÂÍÎÑÒÈ ÃËÈÊÎÏÈÐÎÍÈß Ó ÏÀÖÈÅÍÒÎÂ Ñ ÕÎÇË

®

L. A. Yashina
EVIDENCES OF EFFICIENCY OF GLYCOPYRRONIUM IN COPD PATIENTS
 

Ò. À. Ïåðöåâà
ÑÈÁÐÈ ÁÐÈÇÕÀËÅÐ — ÍÎÂÛÉ Ì-ÕÎËÈÍÎËÈÒÈÊ: ÒÀÊÒÈÊÀ ÂÛÁÎÐÀ ÎÏÒÈÌÀËÜÍÎÉ ÁÐÎÍÕÎËÈÒÈ×ÅÑÊÎÉ ÒÅÐÀÏÈÈ ÏÀÖÈÅÍÒÎÂ Ñ ÕÎÇË

®

T. A. Pertseva
SEEBRI BREETHHALER — NEW ANTIMUSCARINIC AGENT: CHOICE OF OPTIMUM TREATMETN OF COPD PATIENTS
 

Ì. Ì. Îñòðîâñüêèé
ÑÈÁв ÁÐÈÇÕÀÉËÅÐ — Íβ ÌÎÆËÈÂÎÑÒ² ÒÀ ØËßÕÈ ÏÎÊÐÀÙÅÍÍß ÊÎÍÒÐÎËÞ ÑÈÌÏÒÎ̲ ÒÀ ÇÀÃÎÑÒÐÅÍÜ ÕÎÇË

®

M. M. Ostrowski
SEEBRI BREETHHALER — NOVEL OPPORTUNITIES AND THE WAYS OF IMPROVEMENT OF SYMPTOMS AND EXACERBATOINS CJNTROL
 

Ñ. È. Ëåùåíêî
ÍÎÂÛÅ ÏÅÐÑÏÅÊÒÈÂÛ ÐÀÇÂÈÒÈß ÎÒÅ×ÅÑÒÂÅÍÍÎÉ ÈÍÃÀËßÖÈÎÍÍÎÉ ÒÅÐÀÏÈÈ

®

S.I. Leshchenko
PERSPECTIVES OF DEVELOPMENT OF DOMESTIC INHALATION MEDICINE
 

 

ÎÐÈòÍÀËÜͲ ÑÒÀÒÒ² / ORIGINALS
 

Â. Ì. Ìåëüíèê, ². Î. Íîâîæèëîâà, Â. Ã. Ìàòóñåâè÷, À. Ì. Ïðèõîäüêî, ². Â. Áóøóðà
ÅÔÅÊÒÈÂͲÑÒÜ Ë²ÊÓÂÀÍÍß ÕÂÎÐÈÕ ÍÀ ÌÓËÜÒÈÐÅÇÈÑÒÅÍÒÍÈÉ ÒÓÁÅÐÊÓËÜÎÇ Â ÓÊÐÀ¯Í²: ÀÍÀË²Ç ÎÔ²Ö²ÉÍί Ç²ÒÍÎÑÒ²

®

V. M. Melnyk, I. O. Novozhilova, V. G. Matusevych, A. M. Prichodko, I. V. Bushura
EFFECTIVENESS OF TREATMENT OF PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS IN UKRAINE: OFFICIAL REPORTS ANALYSIS

 

Þ. ². Ôåùåíêî, ². Ï. Òóð÷èíà, Ë. Ì. Êóðèê, Ñ. Â. Ìèðîí÷åíêî
ÎÑÎÁËÈÂÎÑÒ² ̲ÊÐÎÁ²ÎÖÅÍÎÇÓ ÂÅÐÕÍ²Õ ÄÈÕÀËÜÍÈÕ ØËßÕ²ÂÓ ÕÂÎÐÈÕ ÍÀ ÁÐÎÍÕ²ÀËÜÍÓ ÀÑÒÌÓ Ó ÔÀDz ÇÀÃÎÑÒÐÅÍÍß

®

Yu. I. Feshchenko, I. P. Turchyna, L. M. Kuryk, S. V. Mironchenko
UPPER RESPIRATORY TRACT MICROBIOCENOSIS IN PATIENTS WITH ASTHMA EXACERBATION

 

Â. À. ß÷íèê
ÑÏÅÊÒÐ ÒÀ ÐÎËÜ ²ÍÔÅÊÖ²ÉÍÈÕ ÇÁÓÄÍÈʲ ÏÐÈ ÇÀÃÎÑÒÐÅÍͲ ÁÐÎÍÕ²ÀËÜÍί ÀÑÒÌÈ

®

V. A. Iachnyk
SPECTRUM AND ROLE OF INFECTIOUS AGENTS IN ACUTE ASTHMA EXACERBATION

 

 

Ñ. ². Ïàí÷óê, Ì. ². Ãóìåíþê, Î. Ï. Òðîõèìåíêî, ². Â. Äçþáëèê
²ÐÓ˲ÖÈÄÍÀ Ä²ß ÄÅÊÀÌÅÒÎÊÑÈÍÓ ÏΠ²ÄÍÎØÅÍÍÞ ÄΠ²ÐÓÑÍÈÕ ÒÐÈÃÅв ²ÍÔÅÊÖ²ÉÍÎÃÎ ÇÀÃÎÑÒÐÅÍÍß ÁÐÎÍÕ²ÀËÜÍί ÀÑÒÌÈ

®

S. I. Panchuk, M. I. Gumeniuk, O. P. Trokhimenko, I. V. Dziublyk
EFFECT OF DECAMETOXINE ON VIRAL TRIGGERS OF INFECTIOUS EXACERBATION OF ASTHMA

 

Â. À. Áåëîãëàçîâ, Þ. Î. Ïîïåíêî
ÝÔÔÅÊÒÈÂÍÎÑÒÜ ÐÎÔËÓÌÈËÀÑÒÀ  ÒÅÐÀÏÈÈ Ó ÁÎËÜÍÛÕ ÑÐÅÄÍÅÒßÆÅËÎÉ È ÒßÆÅËÎÉ ÁÐÎÍÕÈÀËÜÍÎÉ ÀÑÒÌÎÉ

®

V. A. Beloglazov, Yu. O. Popenko
EFFICIENCY OF ROFLUMILAST IN THE TREATMENT IN PATIENTS WITH MODERATE AND SEVERE ASTHMA

 

ß. Î. Äçþáëèê
ÐÀÖ²ÎÍÀËÜÍÀ ÀÍÒÈÁ²ÎÒÈÊÎÒÅÐÀÏ²ß ÕÂÎÐÈÕ ÍÀ ÍÅÃÎÑϲÒÀËÜÍÓ ÏÍÅÂÌÎÍ²Þ ²²² Ê˲Ͳ×Íί ÃÐÓÏÈ

®

Ya. O. Dziublyk
RATIONAL ANTIBIOTIC THERAPY OF GROUP III COMMUNITY-ACQUIRED PNEUMONIA PATIENTS

 

Þ. Ì. Ìîñòîâîé, À. Â. Äåì÷óê, Â. Ë. Ïîáåðåæåöü
ÇÍÀ×ÅÍÍß ÄÈÑÔÓÍÊÖ²¯ ÑÊÅËÅÒÍÈÕ Ì’ßÇ²Â Ó ÔÅÍÎÒÈÏÓÂÀÍͲ ÕÐÎͲ×ÍÎÃÎ ÎÁÑÒÐÓÊÒÈÂÍÎÃÎ ÇÀÕÂÎÐÞÂÀÍÍß ËÅÃÅÍÜ

®

Yu. M. Mostovoy, A. V. Demchuk, V. L. Poberezhets
VALUE OF SKELETAL MUSCLE DYSFUNCTION IN PHENOTYPING OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

 

ÑÒÀÍÄÀÐÒÈ Ä²ÀÃÍÎÑÒÈÊÈ ÒÀ ˲ÊÓÂÀÍÍß / STANDARDS FOR DIAGNOSIS AND TREATMENT
 

Â. Ê. Ãàâðèñþê, Ã. Ë. Ãóìåíþê, Å. À. Ìåðåíêîâà, Ë. Ì. Ïðîöèê, Å. Ì. Ðåêàëîâà
ÀËÃÎÐÈÒÌ ÄÈÀÃÍÎÑÒÈÊÈ ÑÀÐÊÎÈÄÎÇÀ ÎÐÃÀÍÎÂ ÄÛÕÀÍÈß

®

V. K. Gavrysiuk, G. L. Gumeniuk, E. A. Merenkova, L. M. Protsyk, E. M. Rekalova
ALGORITHM FOR DIAGNOSING OF PULMONARY SARCOIDOSIS

 

 

²ÍÔÎÐÌÀÖ²ß / INFORMATION
 

ÐÅÇÎËÞÖ²ß ÍÀÐÀÄÈ ÅÊÑÏÅÐÒ²Â Ç ÏÓËÜÌÎÍÎËÎò¯ «ÑÓ×ÀÑͲ ϲÄÕÎÄÈ ÒÀ Íβ ÌÎÆËÈÂÎÑÒ²  ˲ÊÓÂÀÍͲ ÕÎÇË»
®

RESOLUTION OF BOARD OF PULMONOLOGY EXPERTS «CURRENT APPROACHES AND NOVEL OPPORTUNITIES IN COPD THERAPY»
 

ÏÐÎÖÞÊ ÐÀÄÓ ÃÅÎÐòÉÎÂÈ× (äî 75-ð³÷÷÷ÿ â³ä äíÿ íàðîäæåííÿ)
®

PROTSIUK R. G. (75 years anniversary)
 

ÎÐÈòÍÀËÜͲ ÑÒÀÒÒ² / ORIGINALS
 

Ì. Ì. Îñòðîâñüêèé, ². Î. Ñàâåë³õ³íà
ÂÏËÈ ÁÀÇÎÂί ÒÅÐÀϲ¯ ÍÀ ÎÊÐÅ̲ ÏÀÒÎÃÅÍÅÒÈ×Ͳ ËÀÍÊÈ ÍÅÎÊÎËÀÃÅÍÅÇÓ ÒÀ ËÎÊÀËÜÍÈÉ ²ÌÓÍÍ²É ÇÀÕÈÑÒ ÁÐÎÍÕ²ÀËÜÍÎÃÎ ÄÅÐÅÂÀ ÏÐÈ ÕÐÎͲ×ÍÎÌÓ ÎÁÑÒÐÓÊÒÈÂÍÎÌÓ ÇÀÕÂÎÐÞÂÀÍͲ ËÅÃÅÍÜ

®

M. M. Ostrovskyy, I. O. Savelikhina
EFFECT OF MAINTANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON SEPARATE PATHOGENETIC LINKS OF NEOCOLLAGENESIS AND LOCAL IMMUNE DEFENCE OF A BRONCHIAL TREE

 

Í. Â. Îáóõîâà
ÊËÈÍÈ×ÅÑÊÀß ÝÔÔÅÊÒÈÂÍÎÑÒÜ ÊÎÌÏËÅÊÑÍÎÃÎ ÈÍÃÀËßÖÈÎÍÍÎÃÎ ÈÑÏÎËÜÇÎÂÀÍÈß ÏÐÎÓÐÎÊÈÍÀÇÛ È ËÈÏÎÔËÀÂÎÍÀ ÄËß ÊÎÐÐÅÊÖÈÈ ÄÈÑÁÀËÀÍÑÀ ÐÅÃÈÎÍÀÐÍÎÃÎ (ÝÍÄÎÁÐÎÍÕÈÀËÜÍÎÃÎ) ÖÈÒÎÊÈÍÎÂÎÃÎ ÃÎÌÅÎÑÒÀÇÀ ÏÐÈ ÎÁÎÑÒÐÅÍÈÈ ÕÎÇË Ó ËÈÖ, ÏÅÐÅÍÅÑØÈÕ ÒÓÁÅÐÊÓËÅÇ ËÅÃÊÈÕ

®

N. V. Obukhova
CLINICAL EFFECTIVENESS OF INHALED PROUROKINASE AND LIPOFLAVON FOR CORRECTION OF LOCAL (ENDOBRONCHIAL) IMBALANCE OF CYTOKINE HOMEOSTASIS IN PATIENTS WITH COPD EXACERBATION, CURED FROM PULMONARY TUBERCULOSIS

 

Ê˲Ͳ×Ͳ ÑÏÎÑÒÅÐÅÆÅÍÍß / CLINICAL OBSERVATIONS
 

Ì. Ñ. Îïàíàñåíêî, Î. Å. Êøàíîâñüêèé, Î. Â. Òåðåøêîâè÷, Á. Ì. Êîí³ê, Î. Ê. Îáðåìñüêà, ². Ì. Ïàâëþê
ÏÅÐÂÈÍÍÀ ÍÅÕÎÄÆʲÍÑÜÊÀ ˲ÌÔÎÌÀ ËÅÃÅÍÜ

®

N. S. Opanasenko, A. E. Kshanovsky, A. V. Tereshkovich, B. N. Konik, O. K. Obremska, I. M. Pavluk
PRIMARY PULMONARY NON-HODGKIN'S LYMPHOMA

 

²ÍÔÎÐÌÀÖ²ß / INFORMATION
 

ÀÂÒÎÐÀÌ ÆÓÐÍÀËÜÍÈÕ ÏÓÁ˲ÊÀÖ²É
®

INSTRUCTIONS TO THE AUTHORS
 

 

 



HomeÏîèñê Ïðî èíñòèòóòÍîâîñòè Íàøè èçäàíèÿ Îðèãèíàëüíûå ñòàòòüè Íîâîââåäåíèÿ
ÏàòåíòûÎò÷åòû î ÍÄÐ Ïîäãîòîâêà êàäðîâ Íàó÷íûå ôîðóìû
Èíôîðìàöèÿ äëÿ ñïåöèàëèñòîâÈíôîðìàöèÿ äëÿ íàñåëåíèÿÌåäèöèíñêèå óñëóãè


© Îòäåë ÈÊÒ
ÍÈÔÏ

Îòïðàâèòü E-mail â Èíñòèòóò

www.ifp.kiev.ua